1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
AstraZeneca PLC

AstraZeneca PLC

AZNCF
AstraZeneca PLCUS flagOther OTC
189.90
USD
-2.60
- -
294.40BMarket Cap
AstraZeneca PLC
AZNCF
(Other OTC)

Recent

price

189.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
23.14
24.68
22.18
20.61
21.04
19.55
18.18
17.74
17.43
18.74
20.29
26.39
28.65
29.57
34.89
37.9
37.89
Revenue per Share
5.6
7.29
4.95
2.04
0.98
2.23
2.77
2.37
1.7
1.03
2.44
0.08
2.12
3.84
4.54
6.6
6.6
Basic EPS, GAAP
5.91
4.79
1.85
4.27
3.41
0.42
1.45
1.55
0.98
0.39
1.67
2.65
4.68
4.24
4.69
5.59
5.59
Free Cash Flow per Basic Share
2.34
2.77
2.91
2.76
2.79
2.76
2.82
2.78
2.75
2.76
2.72
2.72
2.82
2.89
2.99
3.21
3.21
Dividend per Share
12.95
13.38
14.49
13.8
10.57
9.61
6.68
6.74
4.74
2.41
4.29
1.48
-0.12
1.22
2.29
7.33
7.33
Book Value per Share
0.96
1.93
-1.9
-2.22
-10.21
-12.61
-17.85
-16.88
-15.49
-13.76
-13.07
-16.29
-14.26
-12.25
-11.18
-6.69
-6.69
Tangible Book Value per Share
1,438
1,361
1,261
1,252
1,262
1,264
1,265
1,266
1,267
1,301
1,312
1,418
1,548
1,549
1,550
1,550
1,550
Basic Weighted Avg Shares
33,269
33,591
27,973
25,806
26,547
24,708
23,002
22,465
22,090
24,384
26,617
37,417
44,351
45,811
54,073
58,739
58,739
Sales/Revenue/Turnover
34.72
33.58
28.19
14.33
11
12.41
21.02
12.06
2.34
7.13
14.71
-0.37
10.17
19.04
18.96
22.69
23.4
Operating Margin (%)
2,741
2,550
2,518
4,583
3,282
2,852
2,357
3,036
3,753
3,762
2,896
4,102
5,254
4,934
5,065
5,490
5,490
Depreciation Expense
8,053
9,917
6,240
2,556
1,233
2,825
3,499
3,001
2,155
1,335
3,196
112
3,288
5,955
7,035
10,225
10,225
Net Income, GAAP
26.38
18.99
18
21.3
0.88
7.92
4.11
- -
- -
20.74
19.71
- -
- -
13.6
18.99
17.49
17.49
Effective Tax Rate (%)
24.21
29.52
22.31
9.9
4.64
11.43
15.21
13.36
9.76
5.47
12.01
0.3
7.41
13
13.01
17.41
17.41
Profit Margin (%)
8,344
7,754
5,145
4,284
-633
1,138
-1,994
-3,233
-701
-2,554
-763
3,650
-3,700
-5,488
-2,039
-1,894
-1,894
Working Capital
9,097
7,338
9,409
8,588
8,397
14,137
14,501
15,560
17,359
16,217
17,994
28,888
23,690
23,222
27,619
26,136
26,136
LT Debt
23,410
23,466
23,946
23,253
19,646
18,509
16,669
16,642
14,044
14,596
15,638
39,287
37,058
39,166
40,871
48,719
48,719
Total Equity
22
24.08
17.62
7.85
8.29
8.28
13.2
- -
- -
3.99
8.73
- -
- -
10.99
11.67
14.45
14.94
Return on Invested Capital (%)
31.44
37.03
23.47
10.37
8.42
14.7
18.06
- -
- -
10.32
17.48
- -
- -
24.7
26.2
31.08
31.09
Return on Capital (%)
45.78
53.85
34.21
14.38
8.05
22.16
33.96
35.32
29.65
29.21
72.91
2.9
- -
- -
258.73
137.17
137.17
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
6,853
6,553
3,486
LT Borrowings
24,714
24,700
24,715
LT Finance Leases
1,272
1,379
1,421
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,550
1,550
1,551
Market Capitalization
214,179
231,725
272,084

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
28,939
29,940
28,723
Cash, Cash Equivalents & STI
7,108
8,182
5,741
Accounts Receivable, Net
14,168
14,338
15,177
Inventories
6,467
6,593
6,557
Total Current Liabilities
33,536
34,054
30,617
Payables & Accruals
- -
- -
- -
ST Debt
6,853
6,553
3,486
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.02%
34.96%
19.2%
Free Cash Flow
66.85%
36.92%
19.18%
Net Income, GAAP
296.66%
576.76%
45.34%
Sales/Revenue/Turnover
9.77%
17.81%
8.63%
Total Cash Common Dividend
3.7%
6.9%
7.39%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
10,879
11,416
11,492
12,024
45,811
2024
12,679
12,938
13,565
14,891
54,073
2025
13,588
14,457
15,191
15,503
58,739

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
1.16
1.17
0.89
0.62
3.84
2024
1.41
1.24
0.92
0.97
4.54
2025
1.88
1.58
- -
1.5
6.6

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
1.97
0.01
0.91
- -
2.89
2024
1.96
0.01
1.02
- -
2.99
2025
2.16
0.01
- -
- -
3.21
Similar Companies
Roche Holding AG (RO.SW)
The Cannaisseur Group, Inc. (TCRG)
Perseus Proteomics Inc. (4882.T)
Zoetis Inc. (0M3Q.L)
Grifols, S.A. (GIFLF)
Eli Lilly and Company (LLY.SW)
Business
AstraZeneca PLC is a multinational biopharmaceutical company primarily engaged in the research, development, manufacture, and commercialization of prescription medicines. It operates in eight therapeutic areas including oncology, cardiovascular, renal and metabolism, respiratory, immunology, neuroscience, rare diseases, and bioscience. AstraZeneca's core product portfolio includes prescription pharmaceuticals such as Tagrisso, Lynparza, Enhertu, Farxiga, Imfinzi, Tezspire, and Fasenra, alongside various vaccines and biologics. The company serves global markets with research and development centers in the UK, Sweden, and the US, and it maintains extensive manufacturing and commercial operations worldwide. Founded in 1999 through the merger of Astra AB and Zeneca Group, AstraZeneca is headquartered at the Cambridge Biomedical Campus in the United Kingdom. Recent major developments include AstraZeneca's completion of several strategic acquisitions to bolster its oncology and rare disease pipelines. In February 2024, AstraZeneca completed the acquisition of Gracell Biotechnologies, enhancing its cell therapy capabilities with Gracell's FasTCAR-enabled dual-targeting CAR-T therapy for cancer and autoimmune diseases. Earlier in 2024, AstraZeneca acquired Fusion Pharmaceuticals, specializing in next-generation radioconjugates for cancer treatment, strengthening its targeted cancer therapy portfolio. The company also acquired Amolyt Pharma in 2024 to expand its presence in endocrine rare diseases. Additionally, AstraZeneca launched AstraZeneca Direct in October 2025, a direct-to-consumer platform allowing patients to purchase select medicines such as Farxiga and Airsupra with home delivery, reflecting a major strategic expansion into patient-focused services. The company continues to invest in advancing drug development with recent FDA approvals, including expansion of indications for Imfinzi in lung cancer treatments. AstraZeneca targets global healthcare markets with a focus on innovation and high-impact therapeutic areas, positioning itself as a leading biopharmaceutical enterprise worldwide. This comprehensive product and service offering, combined with focused acquisitions and the launch of direct consumer pharmacy services, showcases AstraZeneca's strategic evolution and commitment to growth in oncology, rare diseases, and biopharmaceutical innovation.

Company News

APIChatGPT

  • defenseworld.net

    AstraZeneca (OTCMKTS:AZNCF) versus Otsuka (OTCMKTS:OTSKY) Financial Review

  • defenseworld.net

    AstraZeneca (OTCMKTS:AZNCF) Trading Up 1.6% – What’s Next?